Applied Materials vs. Broadcom: Which Semiconductor Stock Is a Better Buy in 2026?

Broadcom is favored over Applied Materials for 2026 after FY2025 revenue rose 23.9% to $63.9B and net income climbed to $23.1B from $5.9B, supported by VMware and strong AI-networking demand. Broadcom generated $26.9B of free cash flow and trades at a lower forward P/E of 29.8x versus Applied Materials' 36.1x, though its higher 0.8x debt-to-equity ratio, customer concentration, VMware integration, and EU antitrust scrutiny remain risks. Applied Materials posted FY2025 revenue of $28.4B, up 4.4%, while net income slipped to $7.0B from $7.2B amid export-control exposure to China and cyclical customer capex risk.

Analysis

The relevant distinction is not "AI exposure" but where operating leverage sits in the cycle. AVGO monetizes hyperscaler AI demand after architecture selection, creating multi-year content pull-through and software cross-sell; AMAT monetizes foundry capacity additions before end-demand is proven. That makes AVGO's earnings visibility stronger over the next 1-3 quarters, while AMAT has greater upside torque if TSM and memory customers broaden wafer-fab-equipment spend in 2027.

The market may be underpricing the asymmetry in AMAT's China and customer-concentration exposure: a modest export-control tightening or delayed node transition can remove high-margin tool revenue quickly, with limited ability to redirect specialized capacity. Conversely, AVGO's AI networking/custom-silicon narrative carries a less visible risk of hyperscaler bargaining power: once internal accelerator programs reach volume, customers can pressure pricing and working-capital terms even if switching costs remain high. VMware is also a margin-supporting but regulatory-sensitive asset; adverse licensing remedies would matter more to AVGO's multiple than to near-term EPS.

Near term, AVGO should retain leadership if hyperscaler capex guidance remains elevated, but a premium-quality narrative can still de-rate sharply if AI semiconductor growth merely decelerates. AMAT is the more contrarian vehicle: its valuation discount only becomes compelling if leading indicators—TSM capex, memory utilization, and China shipment stability—turn upward together. The article's broad claims do not establish those conditions, so this is a relative-value setup rather than an outright AMAT buy today.

Key Decisions for Investors

• Maintain a 3-6 month long AVGO / short AMAT pair, sized beta-neutral: AVGO has superior earnings-duration exposure while AMAT remains more exposed to capex timing and export-policy headlines. Target 10-15% relative outperformance; exit if AVGO's next-quarter AI semiconductor outlook implies material deceleration or AMAT receives a broad China-license clearance.
• For concentrated AI exposure, prefer AVGO over NVDA at the margin only after confirming hyperscaler capex guidance: AVGO offers custom-silicon and networking participation with software cash-flow diversification. Do not add aggressively ahead of earnings if implied volatility prices a move exceeding the historical post-results range.
• Set a catalyst alert on TSM capex revisions, DRAM/NAND utilization, and US export-control announcements over the next 90 days. A synchronized improvement in the first two without new China restrictions would falsify the AMAT-underweight leg and supports rotating into AMAT or a long AMAT / short KLAC relative trade.
• Hedge AVGO downside through 6-month put spreads rather than reducing the core position if regulatory headlines intensify. The thesis breaks if VMware-related remedies force meaningful licensing concessions or if AI revenue guidance is cut despite continued customer capex growth, signaling share loss or pricing pressure.